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Amiodarone is an antiarrhythmic agent known to cause 
prolongation of action potential duration which is re•
flected in the electrocardiogram as a prolongation of the 
QT interval. Prolongation of the QT interval in patients 
dying suddenly was compared with that in patients who 
remained alive to determine whether a difference existed 
between these two groups. The electrocardiogram and 
amiodarone levels were evaluated in 33 patients who 
presented with cardiac arrest and symptomatic ventric•
ular tachycardia in whom no other antiarrhythmic agent 
was found effective in preventing induction of ventric•
ular tachycardia during electrophysiologic studies. There 
were 30 men and 3 women (mean age 62 ± 10 years). 
Twenty-three are alive after a mean follow-up period of 
12 ± 7 months. Ten died: six suddenly, three of non•
cardiac causes and one of congestive heart failure. 
Prolongation of the QT interval has been considered a proar•
rhythmic phenomenon that increases myocardial vulner•
ability (I). Quinidine-induced prolongation of the QT in•
terval (2,3) and the hereditary long QT syndrome (4) are 
often cited as examples of the association of QT prolon•
gation and a proarrhythmic effect. Amiodarone is an an•
tiarrhythmic agent known to cause prolongation of action 
potential duration possibly mediated by changes in voltage•
dependent refractoriness (5-7). Unlike quinidine, prolon•
gation of the QT interval with amiodarone is voltage de•
pendent, not time dependent and changes in refractoriness 
are homogeneous, thus avoiding the possibility of a phar•
macologically induced reentrant mechanism (7). Prolon•
gation of action potential duration has been proposed as a 
mechanism for the antiarrhythmic effect of amiodarone be•
cause this agent acts predominantly on repolarization and 
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Using a two-way analysis of variance, the percent 
change in QT, QTc, JT and JTc intervals before and 
after amiodarone therapy was analyzed. Marked pro•
longation in the QT interval was present in patients who 
remained alive with amiodarone therapy. A significant 
difference in percent QT prolongation was seen between 
the latter patients and those who died suddenly (p < 
0.005). No difference was observed in the percent change 
in QRS interval between the two groups. The levels of 
amiodarone (2.5 versus 3.2 p.g/ml) and its metabolite 
(desethylamiodarone) were not significantly different be•
tween the living patients and those who died suddenly. 
These findings suggest that a prolongation of the QT 
interval may be a marker for the therapeutic antiar•
rhythmic effect of amiodarone. 
(J Am Coli CardioI1986;7:142-7) 
has minor effects on cardiac depolarization. During long•
term administration amiodarone has been shown to cause 
prolongation of the QT interval on the surface electrocar•
diogram, a finding indicative of the time course of ventric•
ular repolarization (8). Whether the QT prolongation seen 
with amiodarone is a marker of drug effect has not been 
established. 
We specifically compared the QT interval with other 
electrocardiographic intervals in patients treated with amio•
darone to determine whether QT prolongation was a marker 
of the antiarrhythmic action of amiodarone. If a difference 
existed in the degree of QT prolongation in patients who 
remained alive and patients who died suddenly, this would 
support the thesis that amiodarone acts by prolonging re•
polarization. If this thesis is correct, QT prolongation could 
be used as a marker for the therapeutic efficacy of amiodarone. 
Methods 
Patients. Electrocardiographic data were obtained in 33 
patients who started amiodarone therapy because ventricular 
tachycardia remained inducible at programmed electrical 
stimulation testing after the administration of conventional 
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and investigational agents. These patients were initially re•
ferred for electrophysiologic testing because of recurrent 
cardiac arrest or symptomatic ventricular tachycardia. No 
patient was excluded from analysis on the basis of a low 
ejection fraction, New York Heart Association class IV 
congestive heart failure or baseline electrocardiographic ab•
normalities. All patients had available a 12 lead electro•
cardiogram before starting amiodarone therapy and match•
ing electrocardiogram and amiodarone levels at the time of 
the electrocardiographic analysis. All patients underwent 
electrophysiologic studies without any antiarrhythmic agents 
and subsequent serial drug testing with a minimum of four 
drugs tested before their discharge on amiodarone. After 
their hospitalization, patients were followed up at 1. 3 and 
6 month intervals with serial electrocardiograms and serum 
amiodarone levels determined for a perspective analysis of 
indicators of clinical outcome. 
Programmed stimulation protocol. After informed 
consent was obtained, electrophysiologic studies were per•
formed with patients in a fasting non sedated state. Pro•
grammed electrical stimulation was performed using a hex•
apolar pacing catheter introduced through the right internal 
jugular vein to the apex of the right ventricle. In patients 
in whom ventricular tachycardia could not be induced from 
the right ventricular apex, the catheter was repositioned to 
the right ventricular outflow tract. A digital stimulator (Bloom 
Associates) was used to deliver square wave electrical im•
pulses 2 ms in duration with amplitude set at least twice 
diastolic threshold. The right ventricle was driven with a 
pacing train of 6 beats at a cycle length of 500 ms with an 
intertrain interval of 8 seconds. 
Serial drug testing. All patients were tested at pro•
grammed electrical stimulation with conventional antiar•
rhythmic agents. A period of five half-lives of the drug was 
allowed before the administration of the next agent. The 
drugs were administered as follows: lidocaine. 1 mg/kg body 
weight bolus followed by a 2 mg/min infusion, procain•
amide, 1.000 to 1.500 mg intravenously at a rate of 100 
mg every 5 minutes; quinidine, 800 mg intravenously at a 
rate of 80 mg every 5 to 10 minutes; disopyramide. 150 to 
200 mg orally every 6 hours; tocainide. 400 to 600 mg 
orally every 8 hours; lorcainide, 100 to 200 mg intrave•
nously at a rate of 10 mg every 5 minutes: flecainide, 2 
mg/kg intravenously administered in three divided doses 
over 15 minutes; cibenzoline, 1 to 2 mg/kg intravenously 
over 20 minutes; N-acetylprocainamide. 18 mg/kg as a con•
stant infusion over 20 minutes; d-sotalol. 1 to 1.75 mg/kg 
continuous infusion over 10 minutes; bethanidine. 5 to 10 
mg/kg at a rate of 80 mg every 5 minutes; pirmenol, 1.1 
mg/kg bolus followed by a 40 j.tg/kg per min infusion. 
Electrocardiographic analysis. Twelve lead electro•
cardiograms before and after amiodarone therapy were re•
viewed by two observers. one of whom did not know the 
clinical status of the patients. Both observers had initially 
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established common guidelines for measurement. The QT 
interval was measured using the limb lead tracings; the 
longest measured QT interval in any of the three leads was 
recorded. Patients with atrial fibrillation were excluded be•
cause of the difficulty in measuring QT intervals accurately 
in this group of patients. The QT interval was also corrected 
for rate using Bazett's formula. QTc = QT/R + R. 
Amiodarone levels. Serum levels of amiodarone and its 
metabolite desethylamiodarone were measured using high 
pressure liquid chromatography sensitive to a concentration 
of 0.5 j.tg/ml. 
Statistical analysis. The mean or percent change from 
the mean ± SD is reported. Difference between means was 
determined using Student's t test (one-tailed) and a two•
way analysis of variance (ANOV A) when appropriate. 
Results 
Patient characteristics (Table 1). Thirty-three patients 
(30 men and 3 women, mean age 62 ± 10 years) were 
studied. Of these, 25 had arteriosclerotic heart disease (19 
had documented myocardial infarction-16 anterior wall, 
2 inferior wall and 1 subendocardial-and 6 had coronary 
artery disease documented by coronary angiography without 
myocardial infarction); 1 had hypertensive cardiomyopathy; 
I had mitral valve prolapse; 2 had cardiomyopathy (diabetic 
and alcoholic) and 1 patient had Lown-Ganong-Levine syn•
drome with supraventricular and recurrent ventricular tachy-
Table 1. Characteristics of 33 Patients Receiving Amiodarone 
Mean age (yr) 62 ± 10 
Sex (M/F) 30/3 
Diagnosi; 
ASHD 25 
WithMI 19 (\ 6 anterior. 2 inferior, 
I subendocardial) 
Without MI 6 
HCVD I 
MItral valve prolapse I 
Cardiomyopathy 2 
Other 4 
Arrhythmia presentation 
CardIac arrest 14 
Symptomatic VT II 
A;ymptomallc VT 8 
NYHA functional class 
I 3 
II 17 
III 10 
IV 3 
L V ejection fractIon 28 ± 6% 
(mean) 
ASHD =0 artenosclerotic disease; F = female; HCVD = hypertensive 
cardIovascular disease; LV = left ventncular; M = male; Ml =0 myo•
cardIal mfarction; NYHA = New York Heart Association; VT = ven•
tricular tachycardia. 
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cardia. Three patients had no evidence of heart disease as 
judged by clinical assessment. chest X-ray film, electro•
cardiogram and echocardiogram. Fourteen patients pre•
sented with out-of-hospital cardiac arrest, 11 had recurrent 
symptomatic ventricular tachycardia and 8 presented with 
asymptomatic ventricular tachycardia (4 with sustained and 
4 with nonsustained tachycardia). These patients had been 
treated with an average of two antiarrhythmic drugs with 
no success before electrophysiologic studies. The mean left 
ventricular ejection fraction for all patients was 28 ± 6%. 
Drug therapy. After treatment with at least four drugs 
failed at electrophysiologic testing, 26 patients were dis•
charged receiving amiodarone as the only antiarrhythmic 
therapy. In an additional seven patients, an effective drug 
was found during electrophysiologic testing but they had 
recurrence of ventricular tachycardia, considered a break•
through on therapy, and subsequently were given amioda•
rone as the only antiarrhythmic therapy. Amiodarone was 
administered orally, 1,200 mg daily for a week, followed 
by an additional week of 800 mg daily and then oral dosing 
between 400 and 600 mg daily with the dose determined 
by the serum amiodarone concentration with a target con•
centration of 2 jLg/ml. 
Drug efficacy (Table 2). Twenty-three patients remain 
alive after a mean follow-up period of 12 ± 7 months (range 
3 to 31). Ten patients died; in six the death can be classified 
as sudden cardiac death, three died of noncardiac causes 
(peritonitis, metastatic colon carcinoma and pulmonary fi•
brosis) and one died of progressive congestive heart failure. 
Of the six patients who died suddenly, the mean time from 
the onset of amiodarone therapy to the time of death was 5 
± 1 months (range 1 to 10). Four of the six patients pre•
sented initially with cardiac arrest, one with symptomatic 
ventricular tachycardia and one with asymptomatic ventric-
Table 2. Characteristics of Patients Who Remained Alive and 
Those Who Died Suddenly During Amiodarone Therapy 
Alive Sudden Death 
No. of patients 23 6 
Mean age (yr) 60 66 
Sex (M/F) 22/1 4/2 
Diagnosis 
ASHD 18 4 
HCVD 0 1 
Mitral valve prolapse 0 
Cardiomyopathy 1 1 
Other 3 0 
Arrhythmia presentation 
Cardiac arrest 7 4 
Symptomatic VT 9 1 
Asymptomatic VT 7 
LV ejection fraction (mean) 28 ± 6% 29 ± 0.3% 
Abbreviations as in Table 1. 
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ular tachycardia. Mean radionuclide ventricular ejection 
fraction for these patients was 29 ± 0.3%. In the four 
patients dying of noncardiac causes, the times of death after 
the onset of amiodarone therapy were 1,3.9 and 29 months. 
The patient who died from progressive congestive heart 
failure died 4 months after starting treatment with amio•
darone. This patient initially presented with cardiac arrest 
and had no recurrence of his arrhythmias while receiving 
amiodarone (Table 2). The levels of amiodarone and its 
metabolite desethylamiodarone were not significantly dif•
ferent between the living patients and those who died sud•
denly; amiodarone levels were 2.5 and 3.2 jLg/ml. respec•
tively, desethylamiodarone levels are 2.1 and 1.8 jLg/ml, 
respectively. Serum electrolytes (K +, Na + +, Ca + + and 
Mg + +) were determined at each patient visit and did not 
significantly differ among the groups. 
Electrocardiographic data (Table 3). The heart rate 
and PR, QRS, QT, QTc, JT and JTc intervals were analyzed 
before and after amiodarone therapy. These intervals and 
the percent change from baseline were compared in patients 
who remained alive and those who died while receiving 
therapy (Fig. I). There was no significant difference in the 
heart rate between the two groups. A slight decrease in heart 
rate (from 73 to 69 beats/min) was seen for the study group 
as a whole during amiodarone therapy, but this decrease 
was not statistically significant. A significant prolongation 
in PR interval was seen during amiodarone therapy from a 
mean of 166 ± 32 to 199 ± 34 ms (p < 0.005). However, 
no significant differences were observed in the absolute or 
percent change in PR interval or QRS duration between 
those living and those dying suddenly. Two-way analysis 
of variance and logistic regression revealed a prolongation 
in the percent change in QT and JT intervals after amio•
darone administration in the patients who remained alive 
with amiodarone therapy contrasted with those dying sud•
denly while receiving the drug; for those alive the percent 
QT prolongation was 13 ± 3 versus 4 ± 11 for those dying 
suddenly, a significant difference (p < 0.(05). If the percent 
change in QT interval of those dying suddenly (4 ± 11) is 
compared with the QT interval of those alive (10 ± 11) 
having received the same dose of amiodarone over the same 
period, those patients who are alive have a significantly 
prolonged QT interval compared with those who died (p < 
0.005). 
Holter monitor data. Five of the six patients dying 
suddenly had ambulatory electrocardiographic (Holter) 
monitoring before and after amiodarone therapy (3 to 6 
weeks after commencing therapy). Of those patients still 
living, 18 were monitored before and after therapy (3 to 6 
weeks after commencing therapy). In the group dying sud•
denly the mean ventricular premature complex frequency 
was 680 ± 79/h and after amiodarone it decreased to 35 ± 
7/h. a 95% reduction. In the group surviving, the mean 
ventricular premature complex frequency before therapy was 
JACC Vol 7, No. I 
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Table 3. Electrocardiographic Intervals of Patients Who Remained Alive and Those Who Died Suddenly During 
Amiodarone Therapy 
Percent Percent 
Heart Rate Change in Change in 
(beats/min) PR (ms) QRS (ms) QT (ms) QTc (ms) ITc (ms) QT JT 
Alive 
Baseline 72 ± 13 166 ± 32 100 ± 26 390 ± 44 427 ± 32 323 ± 32 
Amiodarone 68 ± 10 199 ± 34 112 ± 28 439 ± 42 465 ± 39 349 ± 37 13 ± 3* 14 ± 17* 
Sudden death 
Baseline 66 ± 10 193 ± 37 100 ± 31 405 ± 51 444 ± 79 336 ± 92 
Amiodarone 71 ± 13 220 ± 31 115 ± 31 416/21 438 ± 42 318 ± 53 4 ± II -2 ± 8 
*Slgnificantly different from those dying suddenly, p < 0.005. 
963 ± 172th on average and was decreased to 21 ± 19th, 
a 96% reduction, There was no difference in the percent 
reduction in premature ventricular complexes between the 
two groups. Ventricular tachycardia events were decreased 
from 163 ± 128 to 8 ± 10 in those dying suddenly as 
contrasted with 137 ± 69 to 0.7 ± 16 in those still living. 
The percent decrease in ventricular tachycardia events be•
tween the two groups did not differ significantly. 
Adverse effects. Amiodarone has been well tolerated in 
this group of patients. The major side effects have been 
gastrointestinal, primarily nausea and constipation. Eleva•
tion of serum liver enzymes (glutamic oxaloacetic trans•
aminase, glutamic pyruvic transaminase and alkaline phos•
phatase) to twice their normal values has been seen without 
any serious sequelae. In this series one patient died of pul•
monary fibrosis possibly attributable to amiodarone; how•
ever, the lung biopsy findings were not consistent with the 
Figure 1. Percent increase in QTc intervals in 33 patients receiv•
ing amiodarone therapy. 
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changes typically reported for amiodarone-induced pul•
monary fibrosis (9,10). 
Discussion 
Amiodarone and the QT interval. Measurement of the 
QT interval and its significance have been the subject of 
controversy. To date, the significance of QT prolongation 
remains unanswered (11). The QT interval is still used as 
a reflector of repolarization despite its limitations in mea•
surement. inherent variability, varying T wave configuration 
and dependence of the QT interval on heart rate (12, 13). 
Measurement of the QT interval encompasses a composite 
of many cellular action potentials, and thus it is not an 
absolute measure of action potential duration (14). Given 
these limitations, our study sought to determine whether 
prolongation of the QT interval had any significance in 
guiding therapy or predicting survival of patients treated 
with amiodarone. In this group of patients a significant 
prolongation in QT interval was seen in the patients who 
survived. This prolongation clearly indicates that the effect 
of amiodarone on QT prolongation represents an antiar•
rhythmic effect, and those that manifest this prolongation 
seem to do better. This is in contrast with QT prolongation 
due to heterogeneity of refractoriness due to myocardial 
infarction or drugs such as quinidine that are associated with 
an increased mortality (15-17). 
Analysis of Holter monitoring results shows no difference 
in ventricular premature complex or ventricular tachycardia 
event reduction between the group surviving and the group 
dying suddenly while taking amiodarone. Both groups show 
a significant decrease in frequency and complexity of ven•
tricular ectopic complexes. Amiodarone is usually effective 
in suppressing ectopic activity and this suppression occurs 
in those dying from a suspected arrhythmic event as readily 
as in those surviving. 
QT prolongation and antiarrhythmic action. The pos•
sible mechanism for the differences in clinical outcome in 
patients with a similar prolongation in QT interval has been 
postulated to be different effects on dispersion of refrac-
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toriness and action potential duration. Studies have shown 
that dispersion of refractoriness and increased action poten•
tial duration decrease ventricular fibrillation threshold and 
are arrhythmogenic (18,19). Antiarrhythmic agents such as 
bretylium and procainamide have been shown to decrease 
dispersion of refractoriness in ischemic canine tissues (20.21), 
suggesting that decreasing dispersion of refractoriness is an 
antiarrhythmic effect. A number of investigational antiar•
rhythmic agents such as N-acetylprocainamide and sotalol 
have been shown to be effective in suppressing atrial and 
ventricular arrhythmias (22,23). These agents cause pro•
longation of the QT interval on the surface electrocardio•
gram and prolongation of refractoriness without effects on 
phase 0 of the action potential (24,25). Amiodarone causes 
a prolongation of the action potential duration, voltage•
dependent refractoriness and a resultant homogeneous pro•
longation in myocardial refractoriness (5-7). This uniform 
prolongation makes the requisite fractionation of myocardial 
or His-Purkinje recovery time less likely and thus prevents 
the development of a reentrant tachycardia (7). 
One possibility that could explain our findings is that 
patients who died suddenly died earlier in the treatment 
period than patients who are alive and therefore these pa•
tients did not live long enough to have amiodarone-induced 
QT prolongation. Patients who remained alive receiving 
amiodarone had significant QT prolongation at a mean of 
5 ± 2 months into therapy. This was the same time to death 
seen in the sudden death group who had no significant QT 
prolongation. The clinical arrhythmia presentation was sim•
ilar between those dying suddenly and the group showing 
QT prolongation and an improved survival. Thus, QT pro•
longation acts as a marker for the antiarrhythmic effect of 
amiodarone. 
Amiodarone levels and clinical effects. We found no 
significant difference in serum amiodarone concentration 
between those alive and those dying suddenly. It appears 
that amiodarone levels, although helpful in avoiding drug 
toxicity (26), may not be as helpful in assessing efficacy. 
Other methods such as analyzing myocardial (27) or red 
cell (28) amiodarone levels have been suggested to correlate 
better than serum levels with the efficacy of amiodarone 
because these measurements represent the tissue concentra•
tion of amiodarone that is exerting the pharmacologic effect. 
Several studies have suggested that myocardial levels cor•
relate with electrophysiologic effect (29) and that length•
ening of the QTc interval strongly correlates with antiar•
rhythmic efficacy (30) and plasma (31) and myocardial (32) 
levels. It has been suggested by Debbas et al. (32) that 
lengthening of the QTc interval may be used clinically to 
estimate the myocardial concentration of amiodarone. 
In addition, the changes in QTc interval lengthening and 
shortening during therapy and withdrawal of amiodarone 
parallel the changes seen in the reverse triiodothyronine (T 3) 
level curves during therapy and withdrawal of amiodarone 
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as well (33). The levels of reverse T3 have been reported 
to correlate well with the antiarrhythmic efficacy of amio•
darone and its toxicity (34). The parallel relation of these 
curves therefore highlights the clinical importance of the 
QT interval in guiding amiodarone therapy. Because other 
factors, such as drugs. stress and concurrent illness (35-37), 
affect the levels of reverse T 3, the role of this measurement 
in relation to dosage and survival remains to be clearly 
defined. 
Guidelines for amiodarone therapy. The results of 
programmed electrical stimulation in predicting the efficacy 
of long-term amiodarone therapy also remain controversial. 
Results from different centers have yielded conflicting re•
ports (38-42). The work of McGovem and Ruskin (41) and 
recently the work of Horowitz et al. (42) provide some 
encouraging guidelines suggesting that patients whose ar•
rhythmia is not inducible with amiodarone administration 
have a good outcome, without recurrence of arrhythmia. 
Patients whose arrhythmia remains inducible with amio•
darone tend to have a worse prognosis and additional forms 
of therapy are recommended. The findings of our study 
suggest that QT prolongation during amiodarone therapy is 
a marker of a desirable drug effect. Clearly, QT prolongation 
is the easiest marker to follow up on repeat patient visits. 
Furthermore, our study shows that although QT interval 
prolongation separates those responding to amiodarone ther•
apy from those dying suddenly, amiodarone serum levels 
were not significantly different between the two groups. 
Thus, QT prolongation seems the most useful predictor of 
amiodarone success. These studies suggest that the initial 
loading dose of amiodarone should be continued until sig•
nificant prolongation in QT interval (10 to 15%) is noted 
and further adjustments are made to maintain this percent 
QT prolongation. Clearly the observations are based on a 
small number of patients and our recommendation can be 
considered as only an initial guideline for therapy. 
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